Lifecore Biomedical, Inc.
LFCRHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lifecore Biomedical, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the. The $242.6M market capitalization puts LFCR squarely in micro-cap range for its industry. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Market Cap
$242.6M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-8.21
EPS (TTM)
$-1.27
EPS (Fwd)
$-0.78
ROE
—
ROA
—
Cash
$17.2M
Total Debt
$156.4M
Free CF
—
52W Change
-4.9%
Annual Financials
Cash vs Debt
Where LFCR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LFCR finished 30.14% above its 150-day moving average ($4.91) and 14.72% above its 200-day moving average ($5.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFCR overbought or oversold?
At the October 20, 2026 close, LFCR's RSI(14) was 18.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, LFCR has $17.2M in cash with $156.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Revenue has been uneven over recent years, ranging from $111.3M to $128.9M.
Lifecore Biomedical, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing LFCR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.